Thrivent Financial for Lutherans’s scPharmaceuticals SCPH Stock Holding History

Thrivent Financial for Lutherans’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-856,994	Closed	-$3.27M	–	2580
2025 Q2	$3.27M	Sell	856,994 -179,722	-17%	-$558K	0.01%	1037
2025 Q1	$2.73M	Buy	1,036,716 +51	+0%	+$166	0.01%	1091
2024 Q4	$3.67M	Sell	1,036,665 -12,273	-1%	-$47K	0.01%	1058
2024 Q3	$4.78M	Buy	1,048,938 +14,866	+1%	+$71.9K	0.01%	945
2024 Q2	$4.5M	Sell	1,034,072 -32,632	-3%	-$143K	0.01%	939
2024 Q1	$5.36M	Buy	1,066,704 +17,301	+2%	+$96.9K	0.01%	869
2023 Q4	$6.58M	Buy	1,049,403 +6,814	+0.7%	+$39K	0.01%	759
2023 Q3	$7.42M	Buy	1,042,589 +387,569	+59%	+$3.05M	0.02%	687
2023 Q2	$6.67M	Buy	+655,020	New	+$6.84M	0.02%	759

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Thrivent Financial for Lutherans's SCPH Position: Q3 2025 in Review

Thrivent Financial for Lutherans sold out of scPharmaceuticals (SCPH) in Q3 2025, closing a stake of 856,994 shares — an estimated $3.27M sold.

Thrivent Financial for Lutherans first reported a position in SCPH in Q2 2023 and held it in 9 quarters. The position peaked at $7.42M in Q3 2023. 110 funds tracked by Wall St. Rank hold SCPH as of Q3 2025.

Thrivent Financial for Lutherans reported no remaining scPharmaceuticals position as of Q3 2025 after selling out during the quarter.
Thrivent Financial for Lutherans sold 856,994 scPharmaceuticals shares in Q3 2025, an estimated $3.27M.
Thrivent Financial for Lutherans first reported a position in scPharmaceuticals in Q2 2023 and held it in 9 quarters.
Thrivent Financial for Lutherans's scPharmaceuticals position peaked at $7.42M in Q3 2023.
110 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2025, filed 4 Nov 2025.